New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

Janus kinases (JAK) are a family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) that transduce cytokine-mediated signals through the JAK–STAT metabolic pathway. These kinases act by regulating the transcription of specific genes capable of inducing biological responses in several immune cell subse...

Descripció completa

Dades bibliogràfiques

Autors principals:	Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, Arianna Gonelli, Antonio Giacomo Grasso, Egidio Barbi, Natalia Maximova
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-03-01
Col·lecció:	Pharmaceuticals
Matèries:	Janus kinase GVHD ruxolitinib pediatrics cytokines inflammation
Accés en línia:	https://www.mdpi.com/1424-8247/15/3/374
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!